Scientists develop tree-inspired tech that can pull drinking water straight from the sea: 'A … solution to the emerging water crisis'
The world's growing population, changing climate, and issues with pollution have made getting fresh, drinkable water more difficult and costly than ever.
Over 4 billion people globally are affected by a lack of access to potable water. However, researchers from the University of Waterloo have come up with a more efficient way to turn salt water into fresh water.
A new type of desalination device could make fresh water both more accessible and more affordable.
"Our inspiration comes from observing how nature sustains itself and the way water evaporates and condenses in the environment," said Dr. Michael Tam, a professor from the Department of Chemical Engineering at Waterloo.
"The system we've engineered induces water to evaporate, transports it to the surface, and condenses it in a closed cycle, effectively preventing the accumulation of salt that reduces the efficiency of the device."
Most desalination devices use a membrane to separate the salt from the water. This is effective, but salt collects on the membrane, so over time, less water is able to travel through it. It has to be cleaned off frequently to keep it working at peak efficiency.
By contrast, the research team at Waterloo created nickel foam and coated it with a conductive polymer and pollen particles that respond to heat. It draws up a thin layer of seawater with an action similar to that of a tree's capillaries, separates the water from the salt, and cycles the salt back down into the mixture.
All of this is purely powered by solar energy, which is generated by the material that the researchers created. It is able to harvest solar energy with about 93% efficiency.
Dr. Yuning Li, another Waterloo professor who helped the team measure the efficiency of their device, told Waterloo News, "This new device is not only efficient but also portable, making it ideal for use in remote regions where access to fresh water is limited. This technology offers a sustainable solution to the emerging water crisis."
Where do you get most of your drinking water from?
Straight from the tap
Out of a filter
Bottled water
Cans of sparkling water
Click your choice to see results and speak your mind.
Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool
Yahoo
9 hours ago
- Yahoo
High-potency cannabis use linked to psychosis
More research is showing that the use of high-potency cannabis may elevate the risk of dissociation, including schizophrenia. Nivrita Ganguly speaks with Dr. Leslie Buckley, Chief of Addictions at the Centre for Addiction and Mental Health (CAMH) about what is known and not known about the link between cannabis and psychosis.
Yahoo
10 hours ago
- Yahoo
Scientists develop tree-inspired tech that can pull drinking water straight from the sea: 'A … solution to the emerging water crisis'
Scientists develop tree-inspired tech that can pull drinking water straight from the sea: 'A … solution to the emerging water crisis' The world's growing population, changing climate, and issues with pollution have made getting fresh, drinkable water more difficult and costly than ever. Over 4 billion people globally are affected by a lack of access to potable water. However, researchers from the University of Waterloo have come up with a more efficient way to turn salt water into fresh water. A new type of desalination device could make fresh water both more accessible and more affordable. "Our inspiration comes from observing how nature sustains itself and the way water evaporates and condenses in the environment," said Dr. Michael Tam, a professor from the Department of Chemical Engineering at Waterloo. "The system we've engineered induces water to evaporate, transports it to the surface, and condenses it in a closed cycle, effectively preventing the accumulation of salt that reduces the efficiency of the device." Most desalination devices use a membrane to separate the salt from the water. This is effective, but salt collects on the membrane, so over time, less water is able to travel through it. It has to be cleaned off frequently to keep it working at peak efficiency. By contrast, the research team at Waterloo created nickel foam and coated it with a conductive polymer and pollen particles that respond to heat. It draws up a thin layer of seawater with an action similar to that of a tree's capillaries, separates the water from the salt, and cycles the salt back down into the mixture. All of this is purely powered by solar energy, which is generated by the material that the researchers created. It is able to harvest solar energy with about 93% efficiency. Dr. Yuning Li, another Waterloo professor who helped the team measure the efficiency of their device, told Waterloo News, "This new device is not only efficient but also portable, making it ideal for use in remote regions where access to fresh water is limited. This technology offers a sustainable solution to the emerging water crisis." Where do you get most of your drinking water from? Straight from the tap Out of a filter Bottled water Cans of sparkling water Click your choice to see results and speak your mind. Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet. Solve the daily Crossword
